Evidence map›Paper›PMID 40631552›Full record

ArticleBiochemical Society transactions2025

DIG-DUBs: mechanisms and functions of ISG15 deconjugation by human and viral cross-reactive ubiquitin proteases.

Thomas Bonacci, Michael J Emanuele

Abstract read
In one paragraph

Article in Biochemical Society transactions, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Thomas BonacciDepartment of Pharmacology, Lineberger Comprehensive Cancer Center ,The University of North Carolina at Chapel Hill, Chapel Hill NC 27599, U.S.A.
Michael J EmanueleDepartment of Pharmacology, Lineberger Comprehensive Cancer Center ,The University of North Carolina at Chapel Hill, Chapel Hill NC 27599, U.S.A.ORCID 0000-0003-4104-7449

Funding

Proteostasis signaling in cell cycle controlR35GM153250 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Michael James Emanuele · 2024 to 2026
$1.9M
Deubiquitinases in Cell Cycle ControlR01GM134231 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI EMANUELE, MICHAEL JAMES · 2020 to 2023
$1.6M
NIGMS NIH HHS R01 GM134231NIGMS NIH HHS R35 GM153250
6 · The paper itself

Abstract

Interferon-stimulated gene 15 (ISG15) is a ubiquitin-like protein and, as such, acts as a post-translational modifier that plays a critical role during bacterial and viral infections after interferon (IFN) production. As part of the innate immune system, ISG15 is strongly induced by type I IFNs, and its conjugation to intracellular proteins and viral proteins (ISGylation) allows cells to fight off infection. Importantly, ISGylation is a reversible process that is largely mediated by the cysteine protease USP18 (Ubp43 in mice). As a multifaceted protein, USP18 is a major negative regulator of IFN signaling and the predominant deISGylating enzyme in humans. However, in recent years, additional proteases such as USP16 and USP24 have been reported to also mediate ISG15 hydrolysis. Moreover, coronaviruses and other viral pathogens often encode proteases that possess deISGylating activity, which promotes viral infection by antagonizing ISGylation. Here, we review various enzymes and modes of action employed by human and viral proteases to regulate deISGylation under physiological or pathogenic conditions.

Indexed as

DUBISG15ubiquitinUSP18

Identifiers

PMID40631552
PMCPMC12410001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.